Abpro Corporation, a biotechnology company with the mission of improving the lives of those facing severe and life-threatening diseases with next-generation antibody therapies, and Atlantic Coastal Acquisition Corp. II, a special purpose acquisition company (“Atlantic Coastal”), announce the completion of the closing of their previously announced business combination, which was approved by Atlantic Coastal’s stockholders on November 7, 2024. Abpro Holdings’ common stock is expected to begin trading on The Nasdaq Global Market under the ticker symbol “ABP” and its warrants are expected to begin trading on The Nasdaq Capital Market under the ticker symbol “ABPWW” on Thursday, November 14, 2024.
Read the full article: Abpro Announces Closing of Business Combination with Atlantic Coastal Acquisition Corp. II //
Source: https://www.prnewswire.com/news-releases/abpro-announces-closing-of-business-combination-with-atlantic-coastal-acquisition-corp-ii-302304926.html